- ICH GCP
- Registro de ensaios clínicos dos EUA
- Ensaio Clínico NCT07942285
Sintilimab Plus Ipilimumab N01 and Chemotherapy Versus Sintilimab Plus Chemotherapy as First-Line Treatment for Advanced Gastric or Gastroesophageal Junction Adenocarcinoma With PD-L1 CPS <5
Sintilimab Plus Ipilimumab N01 and Chemotherapy Versus Sintilimab Plus Chemotherapy as First-Line Treatment for Patients With PD-L1 CPS <5 Unresectable Locally Advanced or Metastatic Gastric or Gastroesophageal Junction Adenocarcinoma: A Randomized, Controlled, Multicenter, Phase III Clinical Study
This is a multicenter, randomized, controlled Phase III clinical study designed to evaluate the efficacy and safety of sintilimab plus ipilimumab N01 and chemotherapy compared with sintilimab plus chemotherapy as first-line treatment for patients with unresectable locally advanced or metastatic gastric or gastroesophageal junction adenocarcinoma with a programmed death-ligand 1 (PD-L1) combined positive score (CPS) of less than 5.
Eligible patients will be randomly assigned to receive either sintilimab plus ipilimumab N01 and chemotherapy or sintilimab plus chemotherapy. The study aims to determine whether the addition of ipilimumab N01 to sintilimab plus chemotherapy can improve clinical outcomes in this patient population while evaluating the safety of the combination regimen.
Visão geral do estudo
Status
Intervenção / Tratamento
Tipo de estudo
Inscrição (Estimado)
Estágio
- Fase 3
Contactos e Locais
Locais de estudo
-
-
-
Tianjin, China, 300060
- Tianjin Medical University Cancer Institute and Hospital
-
Contato:
- Ting Deng
- Número de telefone: +86 8008180388
- E-mail: xymcdengting@126.com
-
-
Jiangsu
-
Nanjing, Jiangsu, China, 210008
- Affiliated Drum Tower Hospital, Medical School of Nanjing University
-
Contato:
- Jia Wei
- Número de telefone: +86 25 8310 6666
- E-mail: jiawei99@nju.edu.cn
-
-
Sichuan
-
Chengdu, Sichuan, China, 610041
- West China Hospital, Sichuan University
-
Contato:
- Hongfeng Gou
- Número de telefone: +86-28-85422114
- E-mail: joan_gou1977@163.com
-
-
Critérios de participação
Critérios de elegibilidade
Idades elegíveis para estudo
Aceita Voluntários Saudáveis
Gêneros Elegíveis para o Estudo
Descrição
Inclusion Criteria:
- Aged 18-75 years.
- Histologically confirmed advanced gastric or gastroesophageal junction adenocarcinoma without prior systemic therapy.
- HER2-negative status.
- At least one measurable or evaluable lesion per RECIST v1.1.
- PD-L1 CPS <5, assessed using the PD-L1 IHC 22C3 assay on pretreatment tumor tissue and confirmed by a local or central laboratory.
- ECOG PS 0-1
- Life expectancy ≥3 months.
Exclusion Criteria:
- Pregnant or breastfeeding women, or those planning pregnancy within 6 months after treatment.
- Active tumor bleeding.
- Severe gastrointestinal obstruction or difficulty swallowing tablets.
- Unresolved Grade >1 toxicity from prior anticancer therapy, with protocol-defined exceptions.
- Known DPD deficiency or prior Grade ≥3 fluoropyrimidine-related mucosal toxicity.
- Grade ≥3 hypersensitivity to monoclonal antibodies or chemotherapy components.
- History of seizures, CNS metastases, spinal cord compression, or meningeal metastases.
- Clinically significant cardiovascular or cerebrovascular disease.
- History of severe toxicity requiring permanent discontinuation of immune checkpoint inhibitors or study-related treatment.
- History of noninfectious enteritis requiring corticosteroids within 1 year before treatment.
- Uncontrolled bleeding, bleeding tendency, severe non-healing wounds, ulcers, fractures, or high-risk varices or portal hypertension.
- Intestinal obstruction within 28 days before treatment, unless surgically resolved or completely recovered.
Plano de estudo
Como o estudo é projetado?
Detalhes do projeto
- Finalidade Principal: Tratamento
- Alocação: Randomizado
- Modelo Intervencional: Atribuição Paralela
- Mascaramento: Nenhum (rótulo aberto)
Armas e Intervenções
Grupo de Participantes / Braço |
Intervenção / Tratamento |
|---|---|
|
Experimental: Experimental Arm
Sintilimab Plus Ipilimumab N01 and Chemotherapy |
Patients in the experimental arm will receive a single dose of ipilimumab N01 (3 mg/kg IV), combined with sintilimab (200 mg IV, Q3W) and XELOX or SOX chemotherapy for 6 cycles, followed by maintenance therapy with sintilimab plus capecitabine or S-1. Subsequent dosing of ipilimumab N01 will be determined based on radiological assessments per RECIST v1.1 and safety evaluations. |
|
Comparador Ativo: Active Comparator
Sintilimab Plus Chemotherapy |
Patients in the active comparator arm will receive sintilimab (200 mg IV, Q3W) plus XELOX or SOX chemotherapy for up to 6 cycles, followed by maintenance therapy with sintilimab plus capecitabine or S-1. |
O que o estudo está medindo?
Medidas de resultados primários
Medida de resultado |
Descrição da medida |
Prazo |
|---|---|---|
|
Overall Survival (OS)
Prazo: From randomization to death from any cause, assessed up to 48 months.
|
Defined as the time from randomization to death from any cause |
From randomization to death from any cause, assessed up to 48 months.
|
Medidas de resultados secundários
Medida de resultado |
Descrição da medida |
Prazo |
|---|---|---|
|
Progression-Free Survival (PFS)
Prazo: From baseline to disease progression, assessed up to 24 months.
|
PFS is defined as the time from randomization to the first disease progression per RECIST v1.1 or death from any cause, whichever occurs first. |
From baseline to disease progression, assessed up to 24 months.
|
|
Objective Response Rate (ORR)
Prazo: From baseline until disease progression or other protocol-defined discontinuation criteria, assessed up to 24 months.
|
ORR is defined as the percentage of response-evaluable participants with measurable disease at baseline who achieve a best overall response of confirmed complete response (CR) or partial response (PR) per RECIST v1.1. |
From baseline until disease progression or other protocol-defined discontinuation criteria, assessed up to 24 months.
|
|
Incidence of Adverse Events (AEs)
Prazo: From the first dose through the protocol-defined safety follow-up period, up to 48 months
|
Percentage of participants experiencing AEs, including severity and relationship to study treatment. |
From the first dose through the protocol-defined safety follow-up period, up to 48 months
|
Colaboradores e Investigadores
Datas de registro do estudo
Datas Principais do Estudo
Início do estudo (Estimado)
Conclusão Primária (Estimado)
Conclusão do estudo (Estimado)
Datas de inscrição no estudo
Enviado pela primeira vez
Enviado pela primeira vez que atendeu aos critérios de CQ
Primeira postagem (Real)
Atualizações de registro de estudo
Última Atualização Postada (Real)
Última atualização enviada que atendeu aos critérios de controle de qualidade
Última verificação
Mais Informações
Termos relacionados a este estudo
Outros números de identificação do estudo
- 2026-1221-01
Plano para dados de participantes individuais (IPD)
Planeja compartilhar dados de participantes individuais (IPD)?
Informações sobre medicamentos e dispositivos, documentos de estudo
Estuda um medicamento regulamentado pela FDA dos EUA
Estuda um produto de dispositivo regulamentado pela FDA dos EUA
Essas informações foram obtidas diretamente do site clinicaltrials.gov sem nenhuma alteração. Se você tiver alguma solicitação para alterar, remover ou atualizar os detalhes do seu estudo, entre em contato com register@clinicaltrials.gov. Assim que uma alteração for implementada em clinicaltrials.gov, ela também será atualizada automaticamente em nosso site .